EMA
approval
· 2026-04-01
EMA Authorised: Keppra (levetiracetam) — UCB Pharma SA
Summary
Keppra (levetiracetam) has been authorised in the EU for epilepsy. The marketing authorization holder is UCB Pharma SA.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Epilepsy. MAH: UCB Pharma SA. Decision date: 01/04/2026